Author: admin

DelveInsight’s, “Renal Cancer Pipeline Insight 2023” report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Renal Cancer Pipeline Report

• DelveInsight’s Renal Cancer pipeline report depicts a robust space with 75+ Renal Cancer companies working to develop 80+ pipeline therapies for Renal Cancer treatment.
• The leading Renal Cancer Companies working in the market includes Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
• Promising Renal Cancer Pipeline Therapies in the various stages of development includes Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.
• December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Nivolumab, Cabozantinib, Sunitinib and Ipilimumab. The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma.
• December 2023: Pfizer announced a study of Phase 3 clinical trials for Avelumab (MSB0010718C), Axitinib (AG-013736) and Sunitinib. This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma.
• December 2023: Hoffmann-La Roche announced a study of Phase 2 clinical trials for Tobemstomig, Tiragolumab, Pembrolizumab and Axitinib. This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (also known as RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).

Request a sample and discover the recent advances in Renal Cancer Treatment Drugs @ Renal Cancer Pipeline Outlook Report

The Renal Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Renal Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Renal Cancer clinical trial landscape.

Renal Cancer Overview

Renal cell carcinoma (RCC) is also called hypernephroma, renal adenocarcinoma, or renal or kidney cancer. Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. In early stages Renal carcinoma is symptom free but as the diseases progresses the symptoms may include: lump in the abdomen, fatigue, and unexplained weight loss, blood in the urine, loss of appetite, vision problem, and excessive hair growth. Renal cell carcinoma is the most common type of adult kidney cancer. It is responsible for approximately 85% of kidney neoplasms. Renal cell carcinoma may be clinically asymptomatic for the majority of its course.

Find out more about Renal Cancer Treatment Landscape @ Drugs for Renal Cancer Treatment

Renal Cancer Emerging Drugs Profile

• Atezolizumab : Genentech
• Olaparib: AstraZeneca
• MK-4830 : Merck & Co., Inc
• ALLO-316 : Allogene Therapeutics

Renal Cancer Pipeline Therapeutics Assessment

There are approx. 75+ Renal Cancer companies which are developing the Renal Cancer therapies. The Renal Cancer companies which have their Renal Cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech.

Delve Insight’s Renal Cancer pipeline report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Renal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Renal Cancer Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Renal Cancer Pipeline Therapies @ Renal Cancer Clinical Trials Assessment

Scope of the Renal Cancer Pipeline Report

• Coverage- Global
• Renal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Renal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Renal Cancer Companies- Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
• Renal Cancer Pipeline Therapies- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.

Dive deep into rich insights for new drugs for Renal Cancer treatment, Visit @ Renal Cancer Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Renal Cancer Executive Summary
3. Renal Cancer: Overview
4. Renal Cancer Pipeline Therapeutics
5. Renal Cancer Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. Atezolizumab: Genentech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Olaparib: AstraZeneca
12. Early Stage Products (Phase I)
13. Allogene Therapeutics: ALLO-316
14. Inactive Products
15. Renal Cancer Companies
16. Renal Cancer Products
17. Renal Cancer Unmet Needs
18. Renal Cancer Market Drivers and Barriers
19. Renal Cancer Future Perspectives and Conclusion
20. Renal Cancer Analyst Views
21. Appendix

For further information on the Renal Cancer pipeline therapeutics, reach out to Renal Cancer Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Renal Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

DelveInsight’s, “Parkinson’s Disease Pipeline Insight 2023” report provides comprehensive insights about 140+ Parkinson’s Disease companies and 150+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the Parkinson’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Parkinson’s Disease Pipeline Report

• DelveInsight’s Parkinson’s Disease pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Parkinson’s Disease treatment.
• The leading Parkinson’s Disease companies working in the market include Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
• Promising Parkinson’s Disease Pipeline Therapies in the various stages of development include BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others.
• December 2023: AC Immune SA announced a study of Phase 2 clinical trials for ACI-7104.056 at Dose A. The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 vaccination in patients with early stages of Parkinson’s disease. This is a prospective, multicenter, placebo-controlled, double-blind, randomized study with adaptive features, comprising a screening period of up to 8 weeks, a 74-week double-blind treatment period, and a 26-week post-treatment follow-up period.
• December 2023: Prevail Therapeutics announced a study of phase 1 & 2 clinical trials for Methylprednisolone and Sirolimus. A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson’s Disease With at Least One GBA1 Mutation (PROPEL).
• July 2023: Hoffmann-La Roche announced a study of phase 2 clinical trials for Prasinezumab. This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson’s Disease (PD) who are on stable symptomatic PD medication.
• March 2023: Neurocrine Biosciences announced a study of phase 2 clinical trials for VY-AADC02. The objectives of this study are to assess the efficacy, safety and tolerability of VY-AADC02 in Patients with Parkinson’s Disease with Motor Fluctuations.

Request a sample and discover the recent advances in Parkinson’s Disease Treatment Drugs @ Parkinson’s Disease Pipeline Outlook Report

In the Parkinson’s Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Parkinson’s Disease Overview

Parkinson’s disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine.

Find out more about Parkinson’s Disease Treatment Landscape @ Drugs for Parkinson’s Disease Treatment

Parkinson’s Disease Emerging Drugs Profile

• Tavapadon: Cerevel Therapeutics
• IkT-148009: Inhibikase Therapeutics
• NLY01: Neuraly
• PT320: Peptron

Parkinson’s Disease Pipeline Therapeutics Assessment

There are approx. 140+ key Parkinson’s Disease companies which are developing the Parkinson’s Disease therapies. The Parkinson’s Disease companies which have their Parkinson’s disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics.

DelveInsight’s Parkinson’s Disease pipeline report covers around 150+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Parkinson’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Parkinson’s Disease Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Parkinson’s Disease Pipeline Therapies @ Parkinson’s Disease Clinical Trials Assessment

Scope of the Parkinson’s Disease Pipeline Report

• Coverage- Global
• Parkinson’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Parkinson’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Parkinson’s Disease Companies- Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
• Parkinson’s Disease Pipeline Therapies- BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others.

Dive deep into rich insights for new drugs for Parkinson’s Disease treatment, Visit @ Parkinson’s Disease Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Parkinson’s Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Parkinson’s Disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tavapadon: Cerevel Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Prasinezumab : Roche
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MEDI1341: AstraZeneca
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Neural microtissues: Treefrog Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Parkinson’s Disease Companies
21. Parkinson’s Disease Products
22. Parkinson’s Disease Unmet Needs
23. Parkinson’s Disease Market Drivers and Barriers
24. Parkinson’s Disease Future Perspectives and Conclusion
25. Parkinson’s Disease Analyst Views
26. Parkinson’s Disease Companies
27. Appendix

For further information on the Parkinson’s Disease pipeline therapeutics, reach out to Parkinson’s Disease Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parkinson\’s Disease Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

DelveInsight’s, “Multiple Myeloma Pipeline Insights 2023” report provides comprehensive insights about 75+ Multiple Myeloma Companies and 80+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Myeloma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Multiple Myeloma Pipeline Report

• DelveInsight’s Multiple Myeloma pipeline report depicts a robust space with 75+ Multiple Myeloma companies working to develop 80+ pipeline therapies for Multiple Myeloma treatment.
• The leading Multiple Myeloma Companies working in the market include CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
• Promising Multiple Myeloma Pipeline Therapies in the various stages of development include TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.
• December 2023: Genentech Inc. announced a study of Phase 1 clinical trials for Cevostamab, Tocilizumab, Pomalidomide, Daratumumab and Dexamethasone. This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
• December 2023: AbbVieannounced a study of Phase 3 clinical trials for Pomalidomide, Dexamethasone and Venetoclax. A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
• December 2023: Regeneron Pharmaceuticals announced a study of Phase 1 clinical trials for Linvoseltamab, Daratumumab, Carfilzomib, Bortezomib and Isatuximab. The study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after multiple prior therapies and needed to be treated again.

Request a sample and discover the recent advances in Multiple Myeloma Treatment Drugs @ Multiple Myeloma Pipeline Outlook Report

The Multiple Myeloma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Multiple Myeloma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Multiple Myeloma clinical trial landscape.

Multiple Myeloma Overview

Multiple myeloma (MM) is a clonal plasma cell proliferative disorder characterized by the abnormal increase of monoclonal immunoglobulins. Unchecked, the excess production of these plasma cells can ultimately lead to specific end-organ damage. Most commonly, this is seen when at least one of the following clinical manifestations are present: hypercalcemia, renal dysfunction, anemia, or bone pain accompanied by lytic lesions.

Find out more about Multiple Myeloma Treatment Landscape @ Drugs for Multiple Myeloma Treatment

Multiple Myeloma Emerging Drugs Profile

• Zevorcabtagene Autoleucel: Carsgen Therapeutics
• Descartes 08: Cartesian Therapeutics
• GC012F: Gracell Biotechnology Shanghai Co., Ltd.
• CID-103: CASI Pharmaceuticals
• STI-1492: Sorrento Therapeutics

Multiple Myeloma Pipeline Therapeutics Assessment

There are approx. 75+ key Multiple Myeloma companies which are developing the Multiple Myeloma therapies. The Multiple Myeloma companies which have their Multiple myeloma drug candidates in the most advanced stage, i.e Registered include Carsgen Therapeutics.

DelveInsight’s Multiple Myeloma pipeline report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Multiple myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Multiple Myeloma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn more about the emerging Multiple Myeloma Pipeline Therapies @ Multiple Myeloma Clinical Trials Assessment

Scope of the Multiple Myeloma Pipeline Report

• Coverage- Global
• Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Multiple Myeloma Companies- CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
• Multiple Myeloma Pipeline Therapies- TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.

Dive deep into rich insights for new drugs for Multiple Myeloma treatment, Visit @ Multiple Myeloma Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Multiple myeloma Executive Summary
3. Multiple myeloma Overview
4. Multiple myeloma Pipeline Therapeutics
5. Multiple myeloma Therapeutic Assessment
6. Multiple myeloma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Venetoclax: AbbVie
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. PHE885: Novartis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. ONC 201: Oncoceutics
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. TNB 383B: TeneoBio
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Multiple myeloma Companies
21. Multiple myeloma Products
22. Multiple myeloma Unmet Needs
23. Multiple myeloma Market Drivers and Barriers
24. Multiple myeloma Future Perspectives and Conclusion
25. Multiple myeloma Analyst Views
26. Multiple myeloma Companies
27. Appendix

For further information on the Multiple Myeloma pipeline therapeutics, reach out to Multiple Myeloma Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)

DelveInsight’s, “Acute Lymphocytic Leukemia Pipeline Insight 2023” report provides comprehensive insights about 150+ companies and 160+ pipeline drugs in the Acute Lymphocytic Leukemia pipeline landscape. It covers the Acute Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Acute Lymphocytic Leukemia Pipeline Report

• DelveInsight’s Acute Lymphocytic Leukemia pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline therapies for Acute Lymphocytic Leukemia treatment.
• The leading Acute Lymphocytic Leukemia companies working in the market include PersonGen BioTherapeutics, Novartis Pharmaceuticals, Jazz Pharmaceuticals, Takara Bio Inc., Cellectis S.A., AbbVie, vAutolus Limited, Juventas Cell Therapy Ltd., Pinze Life technology Co. Ltd., Celgene, and others.
• Promising Acute Lymphocytic Leukemia Pipeline Therapies in the various stages of development include Inotuzumab Ozogamicin, CD19 CAR-T cells, clofarabine, Blinatumomab, Marqibo® (vincristine sulfate liposomes injection), and others.
• December 2023: Curon Biopharmaceutical (Shanghai) Co. Ltd. announced a study of Phase 1 & 2 clinical trials for CN201. This study is designed in 2 parts as described below: Phase Ib (dose escalation and expansion) and Phase II. If in Phase Ib it is observed in adult subjects at doses with manageable risk and antitumor activity, studies in pediatric subjects can be initiated to explore safety and efficacy in pediatric subjects, as well as pharmacokinetic profiles.
• December 2023: Takara Bio Inc. announced a study of Phase 1 & 2 clinical trials for TBI-1501. CD19-CAR-T will be administered in the split dose. Phase 2 recommended dose will be applied for phase 1 portion. The investigator assesses efficacy of CD19-CAR-T in accordance with study-specific criteria, at 8 week after the infusion of CD19-CAR-T (or at the time of termination). The investigator also assesses the safety during the follow-up period. Long-term follow-up study is conducted at frequency of once a year for 15 years after the infusion of CD19-CAR-T in reference to guidelines of FDA.
• December 2023: Amgenannounced a study of Phase 3 clinical trials for Blinatumomab and  SOC chemotherapy regimen. The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemotherapy.
• December 2023: H. Lee Moffitt Cancer Center and Research Instituteannounced a study of Phase 2 clinical trials for Tecartus. This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy.

Request a sample and discover the recent advances in Acute Lymphocytic Leukemia Treatment Drugs @ Acute Lymphocytic Leukemia Pipeline Outlook Report

In the Acute Lymphocytic Leukemia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Acute Lymphocytic Leukemia clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Acute Lymphocytic Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Acute Lymphocytic Leukemia Overview

Acute Lymphocytic Leukemia (ALL) (ALL) is also called acute lymphoblastic leukemia. “Acute” means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. “”Lymphocytic”” means it develops from early (immature) forms of lymphocytes, a type of white blood cell.

Find out more about Acute Lymphocytic Leukemia Therapeutics Assessment @ Acute Lymphocytic Leukemia Preclinical and Discovery Stage Products

Acute Lymphocytic Leukemia Emerging Drugs Profile

• CPX-351: Jazz Pharmaceuticals
• JZP-458: Jazz Pharmaceuticals
• UCART22: Cellectis
• JZP-341: Jazz Pharmaceuticals

Acute Lymphocytic Leukemia Pipeline Therapeutics Assessment

There are approx. 150+ key Acute Lymphocytic Leukemia companies which are developing the Acute Lymphocytic Leukemia pipeline therapies. The Acute Lymphocytic Leukemia companies which have their Acute Lymphocytic Leukemia (ALL) drug candidates in the most advanced stage, i.e. phase II/III include Jazz Pharmaceuticals and others.

DelveInsight’s Acute Lymphocytic Leukemia Pipeline Report covers around 160+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Acute Lymphocytic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous.
• Molecule Type

Acute Lymphocytic Leukemia Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Learn more about the emerging Acute Lymphocytic Leukemia Pipeline Therapies @ Acute Lymphocytic Leukemia Clinical Trials Assessment

Scope of the Acute Lymphocytic Leukemia Pipeline Report

• Coverage- Global
• Acute Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acute Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Acute Lymphocytic Leukemia Companies- PersonGen BioTherapeutics, Novartis Pharmaceuticals, Jazz Pharmaceuticals, Takara Bio Inc., Cellectis S.A., AbbVie, vAutolus Limited, Juventas Cell Therapy Ltd., Pinze Lifetechnology Co. Ltd., Celgene, and others.
• Acute Lymphocytic Leukemia Pipeline Therapies- Inotuzumab Ozogamicin, CD19 CAR-T cells, clofarabine, Blinatumomab, Marqibo® (vincristine sulfate liposomes injection), and others.

Dive deep into rich insights for new drugs for Acute Lymphocytic Leukemia Treatment, Visit @ Acute Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Acute Lymphocytic Leukemia Executive Summary
3. Acute Lymphocytic Leukemia Overview
4. Acute Lymphocytic Leukemia Pipeline Therapeutics
5. Acute Lymphocytic Leukemia Therapeutic Assessment
6. Acute Lymphocytic Leukemia– DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Acute Lymphocytic Leukemia Collaboration Deals
9. Late Stage Products (Phase III and Phase II/III)
10. JZP-458: Jazz Pharmaceuticals
11. Mid Stage Products (Phase II)
12. CPX-351: Jazz Pharmaceuticals
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase I)
15. UCART22: Cellectis
16. Drug profiles in the detailed report…..
17. Pre-clinical and Discovery Stage Products
18. JZP-341: Jazz Pharmaceuticals
19. Inactive Products
20. Acute Lymphocytic Leukemia Companies
21. Acute Lymphocytic Leukemia Products
22. Acute Lymphocytic Leukemia Unmet Needs
23. Acute Lymphocytic Leukemia Market Drivers and Barriers
24. Acute Lymphocytic Leukemia Future Perspectives and Conclusion
25. Acute Lymphocytic Leukemia Analyst Views
26. Acute Lymphocytic Leukemia Companies
27. Appendix

For further information on the Acute Lymphocytic Leukemia Pipeline therapeutics, reach out to Acute Lymphocytic Leukemia Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Lymphocytic Leukemia Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)

DelveInsight’s, “Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 120+ Breast Cancer companies and 130+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Breast Cancer Pipeline Report

• DelveInsight’s Breast Cancer pipeline report depicts a robust space with 120+ Breast Cancer companies working to develop 130+ pipeline therapies for Breast Cancer treatment.
• The leading Breast Cancer Companies working in the market include Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
• Promising Breast Cancer Pipeline Therapies in the various stages of development includes Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
• December 2023: Cancer Insight LLC announced a study of Phase 2 clinical trials for Trastuzumab and GM-CSF. In this study, the investigators intend to assess the ability of the combination of trastuzumab and the HER2 vaccine nelipepimut-S (administered with the immunoadjuvant GM-CSF) given in the adjuvant setting to prevent recurrences in patients with high-risk HER2-positive breast cancer. High-risk is defined as those patients that do not achieve a pCR after neoadjuvant therapy with an approved regimen that includes trastuzumab and at least four cycles (12 weeks) of taxane-containing chemotherapy or those who undergo upfront surgery and are found to have greater than or equal to four positive lymph nodes regardless of hormone receptor status or 1-3 positive lymph nodes and are hormone receptor negative.
• December 2023: Seagen Inc. announced a study of Phase 3 clinical trials for Tucatinib, Trastuzumab and Pertuzumab. This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
• December 2023: AstraZeneca announced a study of Phase 3 clinical trials for Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin and Cyclophosphamide. This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.

Request a sample and discover the recent advances in Breast Cancer Treatment Drugs @ Breast Cancer Pipeline Outlook Report

The Breast Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Breast Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Breast Cancer clinical trial landscape.

Breast Cancer Overview

Breast cancer is the most common cancer diagnosed in women, accounting for more than 1 in 10 new cancer diagnoses each year. It is the second most common cause of death from cancer among women in the world. Anatomically, the breast has milk-producing glands in front of the chest wall. They lie on the pectoralis major muscle, and there are ligaments support the breast and attach it to the chest wall. Fifteen to 20 lobes circularly arranged to form the breast.

Find out more about Breast Cancer Treatment Landscape @ Drugs for Breast Cancer Treatment

Breast Cancer Emerging Drugs Profile

• SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
• HLX11: Shanghai Henlius Biotech
• Praluzatamab ravtansine: CytomX Therapeutics
• MCLA-128: Merus N.V.
• DX126 262: Hangzhou DAC Biotech

Breast Cancer Pipeline Therapeutics Assessment

There are approx. 120+ key Breast Cancer companies which are developing the Breast Cancer therapies. The Breast Cancer companies which have their Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Jiangsu HengRui Medicine Co., Ltd.

DelveInsight’s Breast Cancer pipeline report covers around 130+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Breast Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn more about the emerging Breast Cancer Pipeline Therapies @ Breast Cancer Clinical Trials Assessment

Scope of the Breast Cancer Pipeline Report

• Coverage- Global
• Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
• Breast Cancer Pipeline Therapies- Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.

Dive deep into rich insights for new drugs for Breast Cancer treatment, Visit @ Breast Cancer Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Breast Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MCLA-128: Merus N.V.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. DX126 262: Hangzhou DAC Biotech
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ES2B C001: ExpreS2ion Biotechnologies
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Breast Cancer Companies
21. Breast Cancer Products
22. Breast Cancer Unmet Needs
23. Breast Cancer Market Drivers and Barriers
24. Breast Cancer Future Perspectives and Conclusion
25. Breast Cancer Analyst Views
26. Breast Cancer Companies
27. Appendix

For further information on the Breast Cancer pipeline therapeutics, reach out to Breast Cancer Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Breast Cancer Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)

DelveInsight’s, “Non-Small-Cell Lung Cancer Pipeline Insight 2023” report provides comprehensive insights about 135+ Non-Small Cell Lung Cancer Companies and 150+ pipeline drugs in the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Non-Small Cell Lung Cancer Pipeline Report

• DelveInsight’s Non-Small Cell Lung Cancer pipeline report depicts a robust space with 135+ active players working to develop 150+ pipeline therapies for Non-Small Cell Lung Cancer treatment.
• The leading Non-Small Cell Lung Cancer Companies working in the market include BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
• Promising Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, Osimertinib, and others.
• December 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for V940 and Pembrolizumab. The goal of this study is to evaluate V940 plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
• December 2023: AstraZeneca announced a study of Phase 2 clinical trials for Durvalumab, Oleclumab, Monalizumab, MEDI5752, and AZD0171. The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab or AZD0171 and platinum doublet chemotherapy; or MEDI5752 in combination with platinum doublet chemotherapy or datopotamab deruxtecan (Dato-DXd) in combination with durvalumab and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
• December 2023: Gilead Sciences announced a study of Phase 3 clinical trials for Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, and Cisplatin. The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.

Request a sample and discover the recent advances in Non-Small Cell Lung Cancer Treatment Drugs @ Non-Small Cell Lung Cancer Pipeline Outlook Report

The Non-Small Cell Lung Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Non-Small Cell Lung Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Non-Small Cell Lung Cancer clinical trial landscape.

Non-Small Cell Lung Cancer Overview

Non-small-cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small-cell lung cancer (SCLC) and accounts for about 85% of all lung cancers. There are three kinds of NSCLC tumors: a) Adenocancer starts in cells inside air sacs that make mucus and other substances, often in the outer parts of your lungs. It’s the most common kind of lung cancer among both smokers and nonsmokers and people under 45. It often grows more slowly than other lung cancers. b) Squamous cell lung cancer starts in cells that line the inner airways of the lungs.

Find out more about Non-Small Cell Lung Cancer Treatment Landscape @ Drugs for Non-Small Cell Lung Cancer Treatment

Non-Small Cell Lung Cancer Emerging Drugs Profile

• Datopotamab deruxtecan: Daiichi Sankyo
• JDQ443: Novartis
• MRTX849: Mirati Therapeutics
• INBRX-106: Inhibrx

Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 135+ key Non-Small Cell Lung Cancer companies which are developing the Non-Small Cell Lung Cancer therapies. The Non-Small Cell Lung Cancer companies which have their Non-Small-Cell Lung cancer (NSCLC) drug candidates in the most advanced stage, i.e. Phase III include Daiichi Sankyo.

DelveInsight’s Non-Small Cell Lung Cancer Pipeline report covers around 150+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Non-Small-Cell Lung cancer Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Learn more about the emerging Non-Small Cell Lung Cancer Pipeline Therapies @ Non-Small Cell Lung Cancer Clinical Trials Assessment

Scope of the Non-Small Cell Lung Cancer Pipeline Report

• Coverage- Global
• Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Non-Small Cell Lung Cancer Companies- BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
• Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, Osimertinib, and others.

Dive deep into rich insights for new drugs for Non-Small Cell Lung Cancer treatment, Visit @ Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Non-Small Cell Lung Cancer Executive Summary
3. Non-Small-Cell Lung cancer Overview
4. Non-Small Cell Lung Cancer Pipeline Therapeutics
5. Non-Small Cell Lung Cancer Therapeutic Assessment
6. Non-Small-Cell Lung cancer DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase III)
8. Datopotamab deruxtecan: Daiichi Sankyo
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RMC-4630: REVOLUTION Medicines
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. GB 1211: BridgeBio Pharma
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. BBP 398: BridgeBio Pharma.
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Non-Small-Cell Lung Cancer Companies
24. Non-Small-Cell Lung Cancer Key Products
25. Non-Small-Cell Lung Cancer Unmet Needs
26. Non-Small-Cell Lung Cancer Market Drivers and Barriers
27. Non-Small-Cell Lung Cancer Future Perspectives and Conclusion
28. Non-Small-Cell Lung Cancer Analyst Views
29. Non-Small-Cell Lung Cancer Companies
30. Appendix

For further information on the Non-Small Cell Lung Cancer Pipeline therapeutics, reach out to Non-Small Cell Lung Cancer Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)